- Home
- CTOR vs RPTX Comparison
CTOR vs RPTX Comparison
Compare CTOR & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- RPTX
- Stock Information
- Founded
- CTOR 2021
- RPTX 2016
- Country
- CTOR United States
- RPTX Canada
- Employees
- CTOR N/A
- RPTX N/A
- Industry
- CTOR
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- RPTX Health Care
- Exchange
- CTOR NYSE
- RPTX Nasdaq
- Market Cap
- CTOR 63.7M
- RPTX 63.9M
- IPO Year
- CTOR N/A
- RPTX 2020
- Fundamental
- Price
- CTOR $1.97
- RPTX $1.56
- Analyst Decision
- CTOR Buy
- RPTX Strong Buy
- Analyst Count
- CTOR 2
- RPTX 3
- Target Price
- CTOR $6.00
- RPTX $4.50
- AVG Volume (30 Days)
- CTOR 3.1M
- RPTX 717.8K
- Earning Date
- CTOR 08-11-2025
- RPTX 08-05-2025
- Dividend Yield
- CTOR N/A
- RPTX N/A
- EPS Growth
- CTOR N/A
- RPTX N/A
- EPS
- CTOR N/A
- RPTX N/A
- Revenue
- CTOR N/A
- RPTX $1,073,000.00
- Revenue This Year
- CTOR N/A
- RPTX N/A
- Revenue Next Year
- CTOR N/A
- RPTX N/A
- P/E Ratio
- CTOR N/A
- RPTX N/A
- Revenue Growth
- CTOR N/A
- RPTX N/A
- 52 Week Low
- CTOR $0.55
- RPTX $0.89
- 52 Week High
- CTOR $49.00
- RPTX $4.22
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- RPTX 58.19
- Support Level
- CTOR N/A
- RPTX $1.37
- Resistance Level
- CTOR N/A
- RPTX $1.68
- Average True Range (ATR)
- CTOR 0.00
- RPTX 0.08
- MACD
- CTOR 0.00
- RPTX 0.00
- Stochastic Oscillator
- CTOR 0.00
- RPTX 61.29
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.